Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study suggests that individuals who have previously had COVID-19 are highly unlikely to contract the illness again, for at least six months following their first infection.

3d illustration of coronavirus

The study, done as part of a major collaboration between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, was published today as a pre-print.

Despite an estimated 51 million people infected with the virus worldwide, with high levels of transmission ongoing, reports of patients becoming re-infected after already having had COVID-19 are rare. However, up until now there have not been any large-scale studies of how much protection from re-infection people get after COVID-19.

The study, part of a major ongoing staff testing programme supported by the NIHR Oxford Biomedical Research Centre and Public Health England, covered a 30-week period (April – November 2020) with 12,180 health care workers employed at OUH. The health care workers were tested for antibodies to the virus that causes COVID-19 as a way of detecting who had been infected before. The hospital tested staff regularly for COVID-19, both when they became unwell with symptoms and also as part of regular testing of well staff. The researchers then followed whether staff who had been infected before had the same number of new COVID-19 infections as those who had not been infected before.

The full story is available on the University of Oxford website

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.